This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmacology is one of the most fundamental aspects of medication therapy. Without this information, providers cant ensure the safety or efficacy of the medications they prescribe. 1] How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs?
Prior to the launch of those drugs, pharmacological therapy for obesity was something of a backwater, constrained by tolerability and safety issues for older, generic drugs, and lacklustre take-up of newer therapies with limited efficacy. Novo Nordisk recently predicted its obesity sales could reach $3.7 billion in 2025.
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The clinical pharmacology knowledge also isn’t present at smaller companies, he adds.
Angion chalked up a series of trial failures for its hepatocyte growth factor (HGF) mimetic ANG-3777 over the last couple of years, and turned its attention to tyrosine kinase receptor inhibitor ANG-3070 in kidney diseases and fibrotic disorders, before abandoning the drug due to safety concerns in the middle of 2022.
While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.
mAbs have well-established safety profiles, high specificity and affinity and long half-lives – they have been used in drug development for more than 30 years. Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities.
Unsurprisingly, the US FDA has reported a noticeable increase in the number of submissions that use AI/machine learning (ML) components in recent years; in 2021, they received more than 100 submissions wherein AI use was reported. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.
3 Together, these processes determine the drugs concentration in the bloodstream and tissues over time, directly impacting its effectiveness and safety. A highly effective drug (PD) may pose safety concerns if it accumulates due to slow metabolism or excretion (PK). Rang & Dale’s Pharmacology. Accessed January 3, 2025.
They became integral to physiological and pharmacological research during the 19th century and started to be systematically used for drug development during the 20th century. Since then, animal-based testing has been the gold standard for establishing a drug’s safety and efficacy. Clinical Pharmacology and Therapeutics, 104(6), pp.
Despite the recognized need and demand for options to treat female sexual dysfunction, several safety and access issues associated with the use of available options. All this development comes in the backdrop of a wider sense of stigma against the use of pharmacologic options for female sexual function, says Kingsberg.
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.
However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. As these drugs are not licensed for the specific indication of gender-affirming care, collecting safety data on off-label use is not viewed as a priority.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content